Scienza e Tecnologia
Diadem Unveils Novel Findings on Early Alzheimer's Disease Detection Using p53-Specific Antibody at CTAD 2024
Researchers applied U-p53AZ to brain samples from various Braak stages, which track AD progression. The antibody selectively bound to misfolded p53 in AD tissues, with minimal binding in healthy controls. Co-staining with phosphorylated tau (pTau), a key AD marker, reinforced the association between p53 misfolding and tau pathology, suggesting a strong link to AD progression.
Prof. Rakez Kayed stated, "The co-localization of misfolded p53 with phosphorylated tau suggests a mechanistic interaction that warrants further investigation, particularly as a target for early diagnostic intervention." His comments underscore the significance of the findings in identifying new diagnostic and therapeutic strategies.
Dr. Sam Agus , Chief Medical Officer at Diadem, added, "Our results demonstrate that U-p53AZ not only identifies a conformation-specific form of p53 linked to Alzheimer's disease but also correlates with disease severity through Braak staging.
The study expands on prior work (Piccirella et al, JPAD, 2022), positioning U-p53AZ as a robust tool for both early and advanced AD detection. Its potential for clinical application in diagnostic settings is significant, particularly in light of its ability to distinguish AD-related p53 misfolding from normal p53 conformations.
Diadem SpA is a leader in diagnostic solutions for Alzheimer's and neurodegenerative diseases. Based in
Milano, Italy , Diadem focuses on early detection to improve patient outcomes.
For more information, contact:
Diadem:
Michael Rasche
CEO
execadmin@diademdx.com
View original content: https://www.prnewswire.co.uk/news-releases/diadem-unveils-novel-findings-on-early-alzheimers-disease-detection-using-p53-specific-antibody-at-ctad-2024-302291701.html